# Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease

> **NCT05907759** · PHASE2 · RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 28 (estimated)

## Conditions studied

- Lymphoma, Primary Effusion

## Interventions

- **DRUG:** Daratumumab SC

## Key facts

- **NCT ID:** NCT05907759
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-10
- **Primary completion:** 2034-08-01
- **Final completion:** 2035-12-01
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05907759

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05907759, "Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05907759. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*